Bioentrepreneur in 2008

Obviousness is one of the most common reasons for examiners rejecting patent applications. What can you do to limit the chances of such a setback?

Of all the ingredients in a biotech start-up, getting the right people involved is most crucial. Here, Ian Brown, CEO of SDP Technology, provides pointers for putting together a successful business team.

As a company grows, the founding scientist sometimes discovers (and investors often hint) that it's time to leave the CEO spot and hand it to someone with more business experience. To ease the possible shock of the process, consider this transition from day one.

Intellectual property (IP) is a critical asset at most life science start-up companies. Savvy organizational management of IP strategies and assets is essential in optimizing IP value as a sustainable business is built.

A young biotech firm can grow in several ways. The key to success is preparing for them all.

Understanding why licensing works in biotech, and why deals are structured as they are, will help the entrepreneur negotiate.

Intellectual property (IP) is often the most valued asset of biotech firms, especially startups. Two IP lawyers offer guidance on avoiding suits altogether, when to settle them and when to fight.

Biotech companies can extract unexpected value from their patent portfolios to remove roadblocks on the path to commercialization and success.

An industry academic liaison officer and a university technology-transfer professional in the UK canvass their peers to provide some pointers for how to streamline the technology-transfer process between companies and academia.

Striking partnerships is a key ingredient to building a biotech company. In this article, we discuss seven common mistakes that you should avoid during business development.

Starting and sustaining a business in the life sciences is not for the faint of heart. And in an increasingly complex business environment, biotech entrepreneurs should look for complementary partners and new business opportunities to effectively build their companies.

The public markets aren't what they used to be and venture capitalists are seeking investments with shorter timelines. But the good news is several new sources of financing are becoming available.